Antiproliferative effects of cyclocreatine on human prostatic carcinoma cells.

Abstract

Creatine kinase (CK; EC 2.7.3.2) isoenzymes and their substrates have an important function in cellular energy generation and utilization. The brain isoform (CK-BB) has been implicated in cellular transformation processes involving the oncogenic products of the Ela virus and the p53 tumor suppressor gene. Cyclocreatine, an analogue of creatine, has been previously shown to inhibit the growth of a broad spectrum of cancer cells derived from solid tumors. Results reported herein indicate an increased level of creatine kinase activity in human prostate carcinoma cell lines and inhibitory effects of cyclocreatine alone and in combination with adriamycin on the growth of these cells in vitro and in vivo, in immune-deprived mice. Our results suggest the possible use of cyclocreatine in the treatment of prostatic carcinoma.

• Authors: N M Hoosein, K J Martin, M Abdul, C J Logothetis, R Kaddurah-Daouk
• Journal: Anticancer research (Anticancer Res) 1995 Jul-Aug Vol. 15 Issue 4 Pg. 1339-42 ISSN: 0250-7005 [Print] Greece
• PMID: 7654018 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• cyclocreatine
• Doxorubicin
• Creatinine
• Creatine Kinase

Topics

• Animals
• Antineoplastic Agents (pharmacology)
• Creatine Kinase (metabolism)
• Creatinine (administration & dosage, analogs & derivatives, pharmacology)
• Doxorubicin (therapeutic use)
• Humans
• Male
• Mice
• Mice, Inbred BALB C
• Mice, Nude
• Prostatic Neoplasms (drug therapy, pathology)
• Tumor Cells, Cultured